Effects of Raloxifene and Estradiol on Bone Turnover Parameters in Intact and Ovariectomized Rats

Overview

Journal J Physiol Biochem

Specialties Biochemistry
Physiology

Date 2010 Apr 30

PMID 20428990

Citations 13

Authors

S Canpolat

N Tug

A D Seyran

S Kumru

B Yilmaz

Affiliations

Soon will be listed here.

Abstract

This study was designed to investigate effects of raloxifene (RLX) and estradiol on bone formation and resorption in intact and ovariectomized (ovx) rat models. In the intact model, a total of 24 adult female rats were divided into three groups: Controls subcutaneously received saline alone. RLX (2 mg/kg) and estradiol (30 microg/kg) were injected to two groups of animals for a period of 6 weeks at two daily intervals. In the second model, rats (n = 24) were ovx and allowed to recover for a period of at least 3 weeks. Control group received vehicle alone. Remaining rats were divided into two groups and injected with RLX (2 mg/kg) and estradiol (30 microg/kg) for 6 weeks. Urine samples were collected from all animals 24 h after the last drug administration. Urinary deoxypyridinoline (DPD) was measured by ELISA. Serum parathyroid hormone (PTH), calcitonin, and osteocalcin levels were measured by immunoradiometric method. Serum concentrations of alkaline phosphatase (ALP), Ca, and inorganic phosphate were determined by enzymatic-colorimetric method. Lumbar vertebrae (L2) of all animals were dissected out and processed for histopathological evaluation. Removal of ovaries significantly elevated urinary DPD levels (p < 0.01) compared with intact controls. Treatment of both intact and ovx rats with estradiol resulted in significant decreases (p < 0.01) in DPD values. RLX administration had no significant effect in the intact rats, but it remarkably reduced bone turnover in the ovx animals (p < 0.001). Both estradiol and RLX produced conflicting effects on serum ALP, osteocalcin, and PTH levels in both animal models. These findings suggest that RLX exerts its protective effects by reducing bone resorption, similar to that of estradiol, in ovx rats.

Citing Articles

Fam163a knockdown and mitochondrial stress in the arcuate nucleus of hypothalamus reduce AgRP neuron activity and differentially regulate mitochondrial dynamics in mice.

Erdogan C, Yavuz Y, Ozgun H, Bilgin V, Agus S, Kalkan U Acta Physiol (Oxf). 2025; 241(4):e70020.

PMID: 40071489 PMC: 11897941. DOI: 10.1111/apha.70020.

The effect of maternal period nutritional status on oro-sensorial fat perception and taste preference in rats.

Gunalan E, Karagoz M, Civas C, Bilgin V, Erdogan C, Guven A Mol Cell Biochem. 2023; 478(12):2861-2873.

PMID: 36943662 DOI: 10.1007/s11010-023-04703-5.

Thermodynamic Assessment of the Effects of Intermittent Fasting and Fatty Liver Disease Diets on Longevity.

Ongel M, Yildiz C, Baser O, Yilmaz B, Ozilgen M Entropy (Basel). 2023; 25(2).

PMID: 36832594 PMC: 9955784. DOI: 10.3390/e25020227.

Combination of selective androgen and estrogen receptor modulators in orchiectomized rats.

Roch P, Wolgast V, Gebhardt M, Boker K, Hoffmann D, Saul D J Endocrinol Invest. 2022; 45(8):1555-1568.

PMID: 35429299 PMC: 9270269. DOI: 10.1007/s40618-022-01794-7.

Hydroxy-Safflower Yellow A Alleviates Osteoporosis in Ovariectomized Rat Model by Inhibiting Carbonic Anhydrase 2 Activity.

Wang Y, Li X, Deng F, Yin R Front Pharmacol. 2021; 12:734539.

PMID: 34803683 PMC: 8602693. DOI: 10.3389/fphar.2021.734539.

References

Tormey S, Malone C, McDermott E, OHiggins N, Hill A . Current status of combined hormone replacement therapy in clinical practice. Clin Breast Cancer. 2006; 6 Suppl 2:S51-7. DOI: 10.3816/cbc.2006.s.004. View

Epstein E, Silver J, Almogi G, Livni N, Naveh-Many T . Parathyroid hormone mRNA levels are increased by progestins and vary during rat estrous cycle. Am J Physiol. 1996; 270(1 Pt 1):E158-63. DOI: 10.1152/ajpendo.1996.270.1.E158. View

Termine J, Wong M . Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health. Maturitas. 1999; 30(3):241-5. DOI: 10.1016/s0378-5122(98)00092-9. View

Bryant H, Glasebrook A, Yang N, Sato M . An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol. 1999; 69(1-6):37-44. DOI: 10.1016/s0960-0760(98)00147-2. View

Evans G, Bryant H, Magee D, Turner R . Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology. 1996; 137(10):4139-44. DOI: 10.1210/endo.137.10.8828469. View

Clowes J, Riggs B, Khosla S . The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 2005; 208:207-27. DOI: 10.1111/j.0105-2896.2005.00334.x. View

Delmas P, Bjarnason N, Mitlak B, Ravoux A, Shah A, Huster W . Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997; 337(23):1641-7. DOI: 10.1056/NEJM199712043372301. View

Li X, Takahashi M, Kushida K, Inoue T . The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats. J Bone Miner Res. 1998; 13(6):1005-10. DOI: 10.1359/jbmr.1998.13.6.1005. View

Diez J . Skeletal effects of selective oestrogen receptor modulators (SERMs). Hum Reprod Update. 2000; 6(3):255-8. DOI: 10.1093/humupd/6.3.255. View

10.

Erben R, Brunner K, Breig B . Long-term sensitivity of uterus and hypothalamus/pituitary axis to 17beta-estradiol is higher than that of bone in rats. J Bone Miner Res. 2004; 19(11):1827-32. DOI: 10.1359/JBMR.040815. View

11.

Jarvinen T, Kannus P, Sievanen H . Estrogen and bone--a reproductive and locomotive perspective. J Bone Miner Res. 2003; 18(11):1921-31. DOI: 10.1359/jbmr.2003.18.11.1921. View

12.

Seibel M . Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2006; 26(4):97-122. PMC: 1320175. View

13.

Iwamoto J, Yeh J, Schmidt A, Rowley E, STANFIELD L, Takeda T . Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats. Calcif Tissue Int. 2005; 77(2):119-26. DOI: 10.1007/s00223-004-0277-8. View

14.

Reginster J, Devogelaer J . Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clin Orthop Relat Res. 2006; 443:48-54. DOI: 10.1097/01.blo.0000200234.99436.24. View

15.

Castracane V, Kraemer G, Ogden B, Kraemer R . Interrelationships of serum estradiol, estrone, and estrone sulfate, adiposity, biochemical bone markers, and leptin in post-menopausal women. Maturitas. 2005; 53(2):217-25. DOI: 10.1016/j.maturitas.2005.04.007. View

16.

Murano T, Izumi S, Kika G, Haque S, Okuwaki S, Mori A . Impact of menopause on lipid and bone metabolism and effect of hormone replacement therapy. Tokai J Exp Clin Med. 2004; 28(3):109-19. View

17.

Cheung J, Mak Y, Papaioannou S, Evans B, Fogelman I, Hampson G . Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol. 2003; 177(3):423-33. DOI: 10.1677/joe.0.1770423. View

18.

Lane N . Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006; 194(2 Suppl):S3-11. DOI: 10.1016/j.ajog.2005.08.047. View

19.

Davis A, Ellersieck M, Grimm K, Rosenfeld C . The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus. Mol Reprod Dev. 2006; 73(8):1034-44. DOI: 10.1002/mrd.20520. View

20.

Martel C, Picard S, Richard V, Belanger A, Labrie C, Labrie F . Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol. 2000; 74(1-2):45-56. DOI: 10.1016/s0960-0760(00)00087-x. View